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A bstract
Background: Patients w ith chronic kidney disease (CKD) are at a greatly increased risk o f developing cardiovascular 
disease. Recently developed guidelines address multiple risk factors and life-style interventions. However, in current 
practice few patients reach the ir targets.
A  multifactorial approach w ith the aid o f nurse practitioners was effective in achieving treatm ent goals and reducing 
vascular events in patients w ith diabetes mellitus and in patients w ith heart failure. W e  propose that this also holds fo r 
the CKD population.
Design: MASTERPLAN is a multicenter randomized controlled clinical tria l designed to  evaluate whether a multifactorial 
approach w ith the aid o f nurse-practicioners reduces cardiovascular risk in patients w ith CKD. Approximately 800 
patients w ith a creatinine clearance (estimated by Cockcroft-Gault) between 20 to  70 ml/min, w ill be included. To all 
patients the same set o f guidelines w ill be applied and specific cardioprotective medication w ill be prescribed. In the 
intervention group the nurse practitioner w ill provide lifestyle advice and actively address treatment goals. Follow-up will 
be five years. Primary endpoint is the composite o f myocardial infarction, stroke and cardiovascular mortality. Secondary 
endpoints are cardiovascular morbidity, overall mortality, decline o f renal function, change in markers o f vascular damage 
and change in quality o f life. Enrollment has started in April 2004 and the study is on track w ith 700 patients included on 
O ctober 15th, 2005. This article describes the design o f the MASTERPLAN study.
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Background
Patients with chronic kidney disease are at a greatly 
increased risk of developing cardiovascular disease 
(CVD)[1,2]. This is m ost prom inent in patients on renal 
replacement therapy but also firmly established in 
patients with mild renal dysfunction[3]. This increased 
cardiovascular risk in patients with chronic kidney disease 
(CKD) is the resultant of a multitude of risk factors. 
Among these risk factors are: all known traditional risk 
factors, a number of them evidently more prevalent than 
in the general population, risk factors that are associated 
with or worsened by renal insufficiency (anaemia, distur­
bances in calcium-phosphorusbalance, oxidative stress, 
inflammation) and renal insufficiency itself [4-7].
Several guidelines have been formulated, both nationally 
and internationally, to assist physicians in adequately 
reducing cardiovascular risk [8-11]. However it is well 
known that patients do not reach treatment-goals formu­
lated in these guidelines[12]. This has also been estab­
lished in patients with renal disease[13,14]. In patients 
with diabetes mellitus and heart failure a multifactorial 
intervention implemented by nurse-practitioners signifi­
cantly improved metabolic control and reduced cardio­
vascular events [15-18].
Given the high cardiovascular risk and the multitude of 
modifiable risk factors a multifactorial approach could 
very well also be of benefit for patients with CKD. This has 
been suggested several times but has never been proven. 
[4,19,20] Most risk factors that promote CVD also pro­
mote decline of renal function. Effectively addressing 
these risk factors might therefore also delay renal function 
decline[21,22].
Design
The MASTERPLAN study is designed as a multicenter ran­
domized controlled clinical trial with a duration of 5 years 
of follow-up.
Aims & primary outcome
The MASTERPLAN study aims to show that in patients 
with mild to moderate CKD strict implementation of cur­
rent guidelines by a nurse practitioner, with emphasis on 
the use of cardioprotective medication and lifestyle 
changes, results in a reduction of a composite endpoint of 
myocardial infarction, stroke and cardiovascular mortal­
ity.
Cardiovascular morbidity, overall mortality, quality of 
life, percentage of patients achieving treatment goals, 
changes in renal function and changes in markers of vas­
cular damage will be considered as secondary outcomes.
Measurements
Changes in renal function will be documented by annu­
ally measuring creatinine clearance from a 24-hour urine 
sample and measurement of the serum creatinine. Quality 
of life will be assessed through questionnaires that will be 
filled out by all participants annually. Markers of vascular 
damage will be recorded annually in a proportion of the 
patients. These markers address different aspects like 
endothelial function, arterial compliance and atheroscle­
rosis in various vascular beds. Pulse wave analysis (PWA) 
and pulse wave velocity (PWV) will be measured in 
approximately 300 patients. Aortic pulse wave forms and 
aortic pulse wave velocity are indicators of arterial stiff­
ness. PWV has been shown to be an independent predic­
tor for cardiovascular risk[23,24]. PWA and PWV 
measurements have been validated and can be measured 
in a reproducible manner[25]. Carotid intima media 
thickness (CIMT) evaluation through B-mode sonography 
will also be measured in approximately 150 patients. 
Increased CIMT is associated with an elevated risk of car­
diovascular disease[24]. Change in CIMT has been shown 
to result from risk factor modifications in a variety of pop­
u la t io n s ^ ] .  CIMT measurement has been validated and 
shown to be reproducible[27].
Blood pressure will be recorded twice per year using a 
non-invasive automated oscillometric device. Patients 
will stay in a supine position for 30 minutes, blood pres­
sure will be recorded every three minutes. The last five 
measurements will be used for analysis. Conventional 
office readings using the auscullatory method will also be 
documented.
Recruitment and screening
All subjects will be recruited from the outpatient nephrol­
ogy or internal medicine clinic of nine Dutch hospitals. 
Patients are identified by checking their medical records 
for compatibility with the inclusion criteria prior to a reg­
ular outpatient visit. Renal function will be estimated 
using the Cockcroft-Gault formula (with a correction for 
body surface area as of April 15th 2005)(appendix A). The 
Cockcroft-Gault equation has been extensively validated 
and is generally appreciated as a useful tool to estimate 
creatinine clearance[28,29]. The physician will give every 
eligible patient a brief verbal explanation and extensive 
written information about the study. A week later follow- 
up by the nurse practitioner will be performed. Upon ver­
bal consent to participate in the study, the patient will be 
invited to the office. In this visit the in- and exclusion cri­
teria will be checked thoroughly, written informed con­
sent will be acquired and subsequently baseline 
measurements will be performed. The medical ethics 
committees of the participating hospitals have approved 
the conduct of the study.
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Tab le  1: D a ta  collection
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Visit Baseline 1 Visit 2 Visit 3 Visit 4 Visit 5
Month 0 3 6 9 12
Informed Consent x
Demographic data x
Medical history x
In- and exclusion criteria x
Randomization x
Endpoints x x x x
W eight x x x x x
Waist-hip ratio x x
Ankle-Brachial Index x x
RR and HR in sitting position x x x x x
RR 30 minutes Dynamap x x x
Smoking habit x x x x x
Medication use x x x x x
Three monthly Laboratory evaluationa x x x x x
Annual Laboratory evaluation b x x
ECG x x
PWV (Proportion of patients) x x
Carotid-IMT (Proportion of patients) x x
Questionnaires c x x
a: Three monthly Laboratory evaluation: Hematology: Hb, Ht, trombocyte count; Chemistry: sodium, potassium, calcium, phosphate, bicarbonate, 
urea, creatinine, albumin; Urinalysis: spot urine creatinine, albumin, total protein
b: Annual Laboratory evaluation: Hbalc, uric acid, PTH, total-cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides; Urinalysis: 24 hr urine 
sodium, creatinine, albumin, total protein
c: Questionnaires: Quality o f Life: SF-36, EQ-5D; Physical activity: SQUASH; Dietary composition; Erectile dysfunction
Recruitment began in April 2004 and is estimated to con­
tinue until December 2005. About 60% of patients 
deemed eligible by their physician and asked to partici­
pate in the study, actually participate and are included. 
The main reasons for non-participation appear to be: 
reluctance of the patient to changes in drug therapy and 
inability of the patient to attend the required visits. On 
December15, 2005 793 patients had been included.
In- and exclusion criteria
Patients are eligible for inclusion when they fulfill the fol­
lowing criteria:
* The subject is at least 18 years old
* The subject is diagnosed with CKD with a creatinine 
clearance estimated by the Cockcroft-Gault equation 
between 20 and 70 ml/min.
* The subject is able and willing to provide written 
informed consent
The following conditions are considered exclusion crite­
ria:
* A renal transplant less than a year before inclusion
* Acute renal failure or rapidly progressive glomerulone­
phritis established by the treating physician
* Any malignancy less than five years before inclusion 
other than basocellular or squamous cell carcinoma of the 
skin.
* Participation in other clinical trials requiring the use of 
study medication
From April 15 th 2005 until the end of the inclusion the 
Cockcroft-Gault equation was modified to take into 
account body surface area according to recent insights 
into the applicability of formulas to estimate renal func­
tion [30-33]. This modification was approved by the med­
ical ethics committee.
Baseline evaluation and randomization
Table 1 summarizes the data collected at baseline evalua­
tion. After the baseline evaluation, the patient will be ran­
domized to either nurse practitioner care or physician 
care. Randomization to treatment is stratified by center 
and renal transplant status using a web-based randomiza­
tion module and performed in predefined blocks of cer­
tain numbers of patients.
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Tab le  2: Goals and re levan t guidelines fo r cardiovascular risk factors in M A S T E R P L A N
Risk factors Goal Guideline
Blood pressure </= 130/85 mm Hga NFNb8, KDOQ|c[I0]
Proteinuria Protein excretion in urine < 0.5 g/day KDOQ|c[I0]
Lipids K D O Q |c[lI,44 ]
Fasting LDL < 2.6 mmol/l
Anemia NFNb[45],
Hemoglobin concentration > 6.8 mmol/l KDOQ|c[46]
Glucose NHGd [47]
Fasting glucose < 7.0 mmol/l
Non Fasting glucose < 9.0 mmol/l
Calcium and Phosphate metabolism NFNb[8],
Phosphate </= 1.8 mmol/l KDOQ|c[48]
PTH < 18 pMol/l**
Healthy Nutrition GRf[49]
Protein 0.8—1.0 g/kg ideal bodyweight/day
Sodium 2000 mg/day
Fat Reduce fat, unsaturated fats preferred
Energy 30-35 kcal/kg ideal bodyweight/day
Overweight Body mass Index <25 kg/m2
Physical exercise 5*/week 30 minutes moderate exercise NNGBg[50]
Smoking To Quit NFNb[8]
a In case of proteinuria > 1 g/day: 125/75 mm Hg
b NFN: Nederlandse Federatie voor Nefrologie (Dutch Federation for Nephrology) 
c KDOQI: Kidney Disease Outcomes Quality Initiative
d NHG: Nederlands huisartsen genootschap (Dutch College of General Practitioners)
e smaller than three times the upper lim it o f the normal range f GR: Gezondheidsraad (Health Council o f the Netherlands) 
g NNGB: Nederlandse Norm voor Gezond Bewegen (Dutch Standard of Healthful Physical Activity)
Treatment groups
To all patients the same set of guidelines and treatment 
goals, represented in Table 2 and Table 3, apply. Both 
patients and physicians are provided with information 
about the beneficial effects of multifactorial risk factor 
management regardless of treatment allocation. In the 
intervention group nurse practitioners, supervised by a 
qualified nephrologist, will actively pursue lifestyle inter­
vention (physical exercise, nutritional counseling, weight 
reduction and smoking cessation), the use of specified 
cardioprotective medication and the implementation of 
current guidelines. The nurse practitioner will check regu­
larly whether treatment goals have been met and when 
deemed appropriate adjust treatment to achieve target val­
ues. Modification of therapy will be executed according to 
flowcharts that have been derived from current guidelines.
Physician care comprises 'usual care' conform the guide­
lines mentioned in Table 2. In contrast to the intervention 
group and in agreement with real life practice no extra 
incentives to adhere to the guidelines will be supplied.
Tab le  3: S tandard m edication to  reduce cardiovascular risk in M A S T E R P L A N
Medication Recommended dose Point of impact
HMG-CoA Reductase Inhibitor (statin) e.g. atorvastatin 10 mg daily (or comparable 
dose of other statin)
Lipid-metabolism
Acetylsalicylic acid 80 mg daily Thrombocyte aggregation
Folic Acid 5 mg daily Homocysteine metabolism
ACE inhibitor o r Angiotensin Receptor Blocker e.g. enalapril 5 mg twice daily (or comparable Blood pressure, renal function and cardiac pre-
(ARB) dose of other ACE inhibitor) o r irbesartan 75­
150 mg (or comparable dose of other ARB) 
daily
and afterload
a In case of proteinuria > 1 g/day: 125/75 mm Hg b NFN: Nederlandse Federatie voor Nefrologie (Dutch Federation for Nephrology) c KDOQI: 
Kidney Disease Outcomes Quality Initiative d NHG: Nederlands huisartsen genootschap (Dutch College of General Practitioners) e smaller than 
three times the upper lim it o f the normal range f GR: Gezondheidsraad (Health Council of the Netherlands) g NNGB: Nederlandse Norm voor 
Gezond Bewegen (Dutch Standard of Healthful Physical Activity)
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Clinical data
The intervention group will receive follow up by the nurse 
practitioner as often as is indicated by the guidelines and 
the sort of lifestyle intervention the patient receives. Addi­
tional data will be collected for trial purposes quarterly as 
described in table 1. The physician care group will receive 
an automated non-invasive blood pressure measurement 
two times a year. Annually each patient will be invited in 
the office to undergo a series of measurements and to fill 
out questionnaires. At the other time-points (represented 
in Table 1) present clinical data derived from the medical 
records will be recorded in the case report form.
The patients will fill out several questionnaires. Firstly 
quality of life will be assessed using the SF-36 (Dutch ver­
sion) and EQ-5 D (Dutch version) questionnaires[34,35]. 
Secondly the Short Questionnaire to asses health enhanc­
ing physical activity will be given to subjects[36]. Thirdly 
a Food questionnaire developed by the Wageningen Uni­
versity will deliver information about the composition of 
the diet of the subjects[37].
Data management
The entire study is performed according to the ICH-GCP 
guidelines, including on-site monitoring. The data will be 
documented in a case report form, via a validated web- 
based structure. Investigators will fill out the required data 
of a visit in  an Internet application based on PDF files. 
Upon completing the form they will start the submission 
process. Before submission the data are verified and 
passed through an editing process to check for logical 
inconsistencies within the data. Any discrepancies need to 
be corrected before actual submission can take place. The 
data will be sent to a web server located in the data m an­
agement center. The data are immediately transferred into 
a SQL server database.
The questionnaires are all in Teleform format and mailed 
to the data management center. Filled out questionnaires 
are scanned and data are immediately transferred to the 
same database used to store the clinical data. A specified 
validation procedure has been developed to check incon­
sistencies and to generate and process queries.
Endpoint collection and evaluation
The primary endpoint has been defined as follows, based 
on experience in other studies run at the UMCU [38,39].
* Myocardial infarction is defined as evident new ischemic 
changes on an ECG or an established rise and fall pattern 
of cardiac enzymes.
* Stroke is defined as characteristic clinical symptoms of 
stroke accompanied by signs of recent ischemia using an 
appropriate imaging technique (CT-scan or MRI).
* Cardiovascular mortality is defined as death due to myo­
cardial infarction, stroke, ruptured abdominal aneurysm, 
and terminal heart failure. Also sudden death will be 
regarded as part of cardiovascular mortality.
All suspected events, which might contribute to the pri­
mary endpoint, will be evaluated by an independent end- 
point-committee. The committee will evaluate these 
events using definitions for the different events which are 
also used in other Dutch trials [38,39].
Secondary endpoints are collected via clinical data, ques­
tionnaires or specified procedures. The SphygmoCor sys­
tem (pulse wave velocity system and blood pressure 
analysis system, PWV Inc., Sydney Australia) is used to 
assess PWV and to analyze the arterial pulse contours. 
Pulse contours will be obtained by applanation tonom e­
try at the carotid, radial and femoral arteries. Independent 
investigators blinded for treatment allocation of the sub­
ject will perform evaluation of recorded data. CIMT 
assessment will be performed using B-mode ultrasonogra­
phy of both carotid arteries with a 7,5-MHz linear array 
transducer to assess the presence of plaques in the com­
m on carotid artery, bifurcation and internal carotid artery. 
All measurements will be recorded on video and evalu­
ated off-line by independent evaluators blinded for treat­
m ent allocation of the patient [40].
Nurse practitioners
The nurse practitioners are all qualified nurses with sev­
eral years of experience and affinity for nephrology. They 
received extensive education in cardiovascular risk reduc­
tion with emphasis on current guidelines, they were famil­
iarized with the contents of the flowcharts and all were 
uniformly trained in interview techniques to support 
them in implementing lifestyle-modification and maxi­
mizing compliance. Completion of the official Dutch 
Nurse Practitioner training program was no prerequisite 
to function as a nurse practitioner in this study.
Statistical and data analysis
Power analysis
To detect a 50% between-group difference in the trial pri­
mary endpoint with a pre-estimated 5-year event inci­
dence of 13.5% for the control group [16,41], a power of 
80% and a two-sided type I error a  of 5%, at least 640 
patients will have to be included. Taking into account a 
possible loss to follow-up of 15%, at least 740 patients 
will be randomized.
Group sequential analysis
Group sequential analysis will be used to evaluate the pri­
mary endpoints and to m onitor the safety data. Sequential 
analysis is a statistical approach where one conducts sig­
nificance tests over time as the data are collected. Sequen­
Page 5 of 9
(page number not for citation purposes)
Trials 2006, 7:8 http://www.trialsjournal.eom/eontent/7/1/8
tial analysis and its application in clinical trials has been 
described extensively by Whitehead [42]. The general 
approach is as follows. A null hypothesis H0 and an alter­
native hypothesis H1 are formulated for a suitable meas­
ure 9 of treatment difference. For this study with a survival 
type outcome variable, 9 is equal to the logarithm of the 
hazard ratio (HR). H0 is formulated as "no difference in 
the occurrence of the primary endpoints between the two 
trial arms" or 9 = 0 (i.e. HR = 1). The alternative hypothe­
sis H1 is formulated as |9 | > log(0.48) = 0.73 group. Two 
test statistics, Z and V, can be derived depending on the 
type of response variable. Z is a measure of the treatment 
difference; for survival data Z is the observed number of 
events in the control group minus the expected num ber of 
events given treatment equivalence (i.e. the num ber of 
events that would have occurred if the same proportion of 
events was found in the intervention group and in the 
control group) .V reflects the am ount of information 
about 9 contained in Z; for survival data V is approxi­
mately equal to a quarter of the num ber of events 
observed. The sequential analysis requires critical bound­
aries to be specified in advance. These boundaries depend 
on9, the type I error a  and the power 1-p. For each new 
group of patients, values of Z and V are calculated and pre­
sented graphically by plotting Z against V (see Figure1 for 
an illustration of a double-sided sequential test). Based on 
the path of cumulative (Z, V)-points, one of the following 
three decisions is made:
1) the upper or the lower (continuous) boundary is 
crossed: stop the data collection and reject the null 
hypothesis;
2) one of the inner wedge-shaped (dashed) boundaries is 
crossed: stop the data collection and accept the null 
hypothesis;
3) continue the data collection: the cumulative data are 
inadequate to draw a conclusion yet.
With a sequential approach a trial can be stopped earlier, 
on average, than with a fixed sample size approach. Using 
a sequential design between 460 and 716 patients would 
have to be included. (The num ber of patients to be 
included can not be fixed beforehand because patient data 
are analyzed cumulatively and a decision is made to stop 
or to continue the trial according to the interim results.) 
Due to the large difference between the duration of the 
inclusion period and that of the follow-up, it will not be 
possible to implement this potential benefit in the design 
of the trial. Although the length of follow-up in this trial 
in relation to the period scheduled for inclusion does not 
allow for a reduction in sample size other benefits of 
group sequential analysis remain present. Earlier clarity 
on the primary endpoint could allow for earlier stopping
of the trial and thus result in saving time and funds for 
other experiments. Also safety related issues, which are to 
be monitored one-sided, will possibly be identified earlier 
and in this way patient safety is guaranteed throughout 
the trial.
Statistical methods
Group sequential (or interim) analyses will be performed 
using the double triangular test as described by White­
head [42] and implemented in the computer program 
PEST version 4 [43]. The analyses will be performed by an 
independent data safety monitoring board (DSMB) con­
sisting of a nephrologist, an internist and a statistician. 
They meet every 6 months to m onitor various aspects of 
the study, including recruitment, adverse events and 
interim analyses of the primary endpoints.
The results of the study will be analyzed following the 
'intention to treat' principle. This means that subjects will 
be analyzed according to the group they have been allo­
cated to by the randomization. Results will be presented 
as Kaplan-Meier curves for the two treatments and the dif­
ference between the treatments will be analyzed using a 
log-rank test. For the primary outcome variables the log­
rank test will be adjusted for the effect of the cumulative 
data analyses. Results will be presented for all cause m or­
tality and CV events separately.
The primary analysis of CIMT progression wiw ll be per­
formed using a linear random coefficient (Laird-Ware) 
model using real visit days, treatment and clinical center 
as independent variables. For each participant, the inter­
cept and slope of CIMT change over time is assumed to be 
a normally distributed random variable with different 
means for the two treatment groups. The mean slope for 
the nurse practitioner group will be compared to that for 
nephrologist-care group using linear contrasts and a 5% 
significance level. Additional exploratory analyses will 
evaluate the impact of including baseline IMT, lumen 
diameter, ultrasound reader, and center as additional co- 
variates.
The data analytic approach to arrive at the PWV outcome 
variable is similar to that of the CIMT outcome. Adjust­
ments that will be taken into account in the estimates are 
changes in MAP and changes in heart rate, since both are 
closely related to PWV.
Discussion 
Limitations of the study
There are several limitations to the study mostly due to 
unavoidable decisions.
1. Although many patients receiving standard care are not 
treated according to current guidelines it is ethically not
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possible to withhold information and advice on these 
guidelines from the control group. Therefore all patients 
receive information about risk factor management and all 
physicians are informed about the treatment goals. This 
may result in improved treatment in the control group 
thereby attenuating the potential difference in cardiovas­
cular events between the two treatment arms.
2. Due to the sort of intervention blinding is not possible 
for patients or physicians. This is unavoidable since some 
physicians will be treating or supervising both physician 
care and nurse practitioner care patients. Again, attenua­
tion of group differences may occur.
3. The multifactorial intervention will make it impossible 
to single out one aspect of the intervention as being the 
most beneficial. Since trials establishing the exact amount 
of risk reduction per risk factor intervention are missing in 
patients with mild to moderate renal dysfunction, such 
information would have been most useful. As pointed out 
earlier however the choice for a multifactorial design has 
received ample consideration. As a consequence of this 
choice for a multifactorial approach sample size is too 
small to allow for a definite statement about a single risk 
factor. A study large enough to establish the benefits of 
one aspect of the intervention would require thousands of 
patients and the logistics and funding necessary to realize 
this are not present for investigator driven research.
Conclusion
Cardiovascular risk in patients with CKD is very high, 
multifactorial in origin and present early in the course of 
CKD. Effectively addressing risk factors will reduce cardi­
ovascular risk significantly. A multifactorial approach 
with the aid of nurse practitioners has been shown to be 
effective in other high-risk populations. The MASTERP­
LAN trial is designed to establish the effects of such a mul­
tifactorial approach in patients with mild to moderate 
renal insufficiency. The MASTERPLAN trial is a unique 
multicenter randomized clinical trial because it investi­
gates the effects of a multifactorial approach to reduce car­
diovascular events in a population until now rarely 
targeted despite a huge cardiovascular risk. The employ­
m ent of the nurse practitioner provides a valuable means 
of implementing the multifactorial intervention.
Appendix A
The Cockcroft-Gault equation
Clcr (ml/min) = (140 - age (in years)) x  t o n i g h t :  (in  kg) x  88,5 ( x  0 M  for females) 
72 x serum creatinine (in m ol/l )
The Cockcroft-Gault equation modified to correct for 
body surface area (effective from april 15 th 2005).
Crcl (ml/min/ 1.73 m2) = ( 140-age) x  M y w d j ^  (in kg) x 88,5 (x 0.85 for females) x 1 7 3  
72 x serum creatinine (in m ol/l ) BSA
Body Surface Area will be estimated using the formule by 
Dubois and Dubois.
Appendix B 
Masterplan study group
Peter J. Blankestijn
Michiel L. Bots 
Marjolijn van Buren 
Marc A.G.J. ten Dam 
Karin A.H. Kaasjager 
Gerry Ligtenberg 
Yvo W. Sijpkens 
Henk E. Sluiter 
Peter J. van de Ven 
Gerald Vervoort 
Louis-Jean Vleming 
Jack F.M. Wetzels 
Arjan D. van Zuilen 
Participating centers
* Canisius Wilhelmina Hospital, Nijmegen, The Nether­
lands
* Deventer Hospital, Deventer, The Netherlands
* Haga Hospital, Location Leyenburg, The Hague, The 
Netherlands
* Haga Hospital, Location Rode Kruis, The Hague, The 
Netherlands
* Leiden University Medical Center, Leiden, The Nether­
lands
* Medical Center Rijnmond Zuid, Rotterdam, The Nether­
lands
* Rijnstate Hospital, Arnhem, The Netherlands
* Radboud University Nijmegen Medical Center, 
Nijmegen, The Netherlands
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* University Medical Center Utrecht, Utrecht, The Nether­
lands
Event committee
* Dr. J.J. Beutler, nephrologist, Jeroen Bosch Hospital, 's 
Hertogenbosch, The Netherlands, (chair)
* Dr.J.D. Banga, internist, University Medical Center 
Utrecht, Utrecht, The Netherlands,
* Dr. A.P. Van Dijk, cardiologist, Radboud University 
Nijmegen Medical Center, Nijmegen, The Netherlands,
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